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Summary
The past decade has witnessed the unveiling of a powerful new generation of genetically-engineered
mouse (GEM) models of human cancer, which are proving to be highly effective for elucidating
cancer mechanisms and interrogating novel experimental therapeutics. This new generation of GEM
models are well-suited for chemoprevention research, particularly for investigating progressive
stages of carcinogenesis, identifying biomarkers for early detection and intervention, and pre-clinical
assessment of novel agents or combinations of agents. Here we discuss opportunities and challenges
for the application of GEM models in prevention research, as well as strategies to maximize their
relevance for human cancer.
Introduction: Modeling cancer prevention in genetically-engineered mutant
mice
Despite many recent advances, cancer remains a leading cause of death in the United States.
While many patients have benefited from the development of new approaches for diagnosis
and treatment; ultimately, the most successful strategy for eradicating cancer will entail
discovery of more effective means for its prevention, early detection, and early intervention.
While genetically-engineered mouse (GEM) models of human cancer can greatly augment
prevention research, to date, these models have not been widely exploited for prevention
research. Here we consider the progress, potential, and pitfalls of using GEM models for
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prevention research, concluding with a discussion of how we can best capitalize on these
models in the future. For a more in depth discussion of GEM models in cancer prevention the
reader is referred to (1).
GEM models of human cancer refer to mouse strains in which the genome has been manipulated
to achieve gain- or loss- of oncogene or tumor suppressor gene function, respectively, the
consequences of which are manifested in tumor phenotypes (2). Similar to chemically-induced
rodent models, which historically have been widely used in prevention research, GEM models
provide an opportunity to investigate carcinogenesis in the context of the whole organism.
However, GEM models are distinct from chemically-induced rodent models, since their tumor
phenotypes are induced by manipulating a specific gene or genetic pathway rather than
induction with carcinogens and/or other cancer promoting agents. Thus, GEM models enable
the assessment of specific molecular pathways for tumorigenesis in the context of the whole
organism.
GEM models are also distinct from xenograft models, which are typically based on the
propagation of human tumors and/or cell lines in immune-deficient mice. While xenograft
models have the obvious advantage of being developed from human cancer cells, they are often
derived from established tumors or cancer cell lines (and very often from advanced tumors or
metastases), and therefore are unlikely to precisely model early events in carcinogenesis.
Moreover, since xenografts are propagated in immunodeficient mice, they do not recapitulate
the contributions of the tumor microenvironment, bacterial flora, or host immune system for
carcinogenesis, which is of considerable concern as it is becoming increasingly apparent that
these play critical roles in carcinogenesis, particularly at early disease stages (3–5).
However, critics of GEM models argue that their relevance for human cancer has not been
established (6), and cite examples in which studies in mouse models have not been validated
to human cancer (see below). On the other hand, proponents of GEM models contend that the
problem is not that the models aren’t relevant, but that the experimental parameters have not
been designed in such as way as to effectively translate studies from mice to human cancer
(7–9). Indeed, the applicability of prevention studies done in GEM models of human cancer
will invariably be dependent on the choice of the model, the design of the experiment, and
many other logistical issues. Ultimately, for studies in GEM models to be applicable to humans,
the models need to be appropriately chosen such that their biological and pathological
properties are relevant for the experimental question being asked and, conversely, the
experimental design of the study should be analogous to design of prevention research in
humans.
Accordingly, it is imperative to establish criteria for evaluating the relevance of a particular
GEM model for a given experimental paradigm. Such criteria should include: (1) Pathological
analyses — does the model display histological and pathological features in common with
human cancer or a sub-type thereof? (2) Disease evolution — does the model recapitulate the
stages of disease progression as occurs in humans? (3) Tumor microenvironment — does the
model effectively recapitulate the contribution of host factors including the tumor stroma,
bacterial flora, and immune response for cancer progression? (4) Molecular pathways — does
the model display relevant genetic, genomic, epigenetic, and/or proteomic alterations that are
known to be relevant for their human counterpart? (5) Environmental factors — do hormonal,
dietary, or other factors affect disease progression in the mouse models in a similar way as they
do in humans?
Notably, it is often the case that in the course of characterizing these criteria for GEM models,
new insights emerge that are relevant for understanding the molecular and biological properties
of the human disease. Thus, analyses of GEM mice have elucidated critical biological
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mechanisms of tumorigenesis that provide new insights into human cancer, including as the
critical role of telomere length in disease pathogenesis (10) and more recently the role of
cellular senescence in tumor suppression in vivo (11). Similarly, comparative analyses of the
molecular properties of mouse and human tumors have enabled the comprehensive analyses
of global alterations in genomic pathways (12), as well as the identification of specific genes
that are novel biomarkers of disease outcome in humans (13,14).
In the discussion that follows, we first provide a historical perspective on the types of GEM
models that are available for prevention research (Table 1). Following which, we discuss past
experiences using mouse models in prevention research and consider how these past
experiences can impact the design of future studies. Finally, we consider opportunities for using
GEM models as well as obstacles that need to be overcome to effectively capitalize on their
application for prevention research.
The first generation: the oncomice
Historically, the first GEM models of human cancer were the transgenic models, the so-called
“oncomice”, in which a particular gene (most often an oncogene and in many cases SV40T
antigen) was expressed in the mouse genome via a tissue-specific promoter, resulting in a
cancer phenotype (reviewed in (15)) (Table 1). These oncomice provided some of the earliest
GEM models for pancreatic, breast, prostate, and brain cancer, and their analyses over the past
two decades have provided the foundation for many investigations of cancer mechanisms, and
have been used in pre-clinical studies for both prevention and experimental therapeutics.
As is the case for all model systems, transgenic models have certain advantages as well as
limitations. One of the major reasons transgenic models remain popular is their relative
simplicity of design and propagation; these models provide a straightforward means of
assessing the consequences of gain-of-function of particular genes for tumorigenesis.
However, disease evolution may be dissimilar to that of most human cancers, since it is initiated
by expression of an exogenous gene and typically not stoichastically. Furthermore, the
generation of transgenic models is, by definition, dependent on the availability of suitable
promoters, defined as those that achieve targeted expression in the appropriate cell types and
in the appropriate spatial-temporal domains such that the resulting cancer phenotypes resemble
their human counterparts. While this may seem a high bar to achieve, in practice several
promoters have been effectively utilized for the development of transgenic models that
recapitulate the progression and phenotypic features of their counterpart human cancer (15).
The second generation: loss-of-function of tumor suppressors
The next phase in the evolution of GEM models of cancer was based on targeted deletion of
tumor suppressor genes in the germline (Table 1). Among the first of such models were those
resulting in targeted deletion of Trp53 and Rb1, which develop a spectrum of cancer phenotypes
(2). Notably, their tumor spectrum was found to be dissimilar to the consequences of mutations
of these tumor suppressor genes in human cancer, which has been offered as an indictment of
the lack of relevance of these GEM mouse models for human cancer. However, subsequent
studies have shown that gain of function mutations of Trp53, in contrast to null mutations, lead
to more similar tumor phenotypes to human cancer (16,17), and have also shown that the
occurrence of a retinoblastoma phenotype in Rb1 mutant mice is dependent on alterations of
other genes (18). Interestingly, although these and other germ-line mutant mouse alleles have
been extensively utilized to investigate cancer mechanisms, to date they have not been widely
used for cancer prevention studies.
Another potential limitation of germline mutant alleles is that they are more similar to inherited
forms of cancer than sporadic forms, which are far more prevalent in humans. However,
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improved technologies for manipulating the mouse genome have led to more sophisticated
gene targeting approaches, wherein selected genes of interest are conditionally inactivated (or
conditionally activated) in spatially- and temporally-restricted domains. These conditional
models include those based on loss-of-function of tumor suppressor genes, such as Trp53 and
Pten, as well as gain-of-function of oncogenes, such as Kras (reviewed in(2)). Conditional
gene targeting offers many advantages over traditional gene targeting in the germ-line, such
as overcoming the problem of embryonic lethality, which often precludes analyses of
homozygous germ-line deletion of tumor suppressor genes, such as Rb1 and Pten. In addition,
selective gene targeting to specific cell/tissue compartments often yields GEM models with a
more restricted spectrum of tumor phenotypes, which are more suitable for pre-clinical studies.
The “next” generation of mouse models of cancer
Conditional models depend on having suitable approaches for achieving targeted gene deletion/
activation in spatially- and temporally-restricted domains. Thus, what has truly revolutionized
the application of such models for human cancer has been the tremendous advances in recent
years for achieving highly restricted expression of Cre recombinase in tissue specific
compartments using transgenic or “knock-in” approaches, as well as the potential to selectively
regulate Cre activity using derivatives that are activated by tamoxifen or other compounds
(7,19) (Table 1). Furthermore, technological improvements have enabled the introduction of
Cre recombinase into specific tissue sites using adeno- or lentiviral approaches. For example,
selective delivery of Cre recombinase via an adenoviral delivery into the lungs of a mouse
allele harboring a conditionally-activatible Kras allele has led to the generation of a mouse
model of lung cancer, which has provided new insights for stratifying human patients with
lung cancer, has led to the identification of lung progenitor cells, and has been effectively used
for pre-clinical studies for experimental therapeutics and prevention research (20–23).
Other important technological approaches include the utilization of systems in which gene
expression can be turned on or off using tetracycline-regulated activators affecting the
responsive promoters driving the transcription of a gene of interest (24), which has been applied
to several organ systems, including lung, lymphoid and breast to study the roles of oncogenes
in tumor maintenance and mechanisms of tumor recurrence (25,26). Other approaches for
manipulating gene expression include targeted expression of the receptor to the TVA chicken
virus in specific mouse tissues, thereby providing a means to transduce the target tissues with
viruses that will express specific genes of interest (27), which has led to the generation of
valuable models of CNS and other tissues (28). Moreover, as an alternative to gene targeting
approaches, new technologies for the stable “knock-down” of gene expression in vivo by
delivery of RNAi moieties are proving to be effective for developing mouse models of cancer
(29,30). Finally, major technological advances in small animal imaging approaches, which
now enable the effective visualization of tumors in vivo has made a huge impact on the effective
utilization of GEM models and will surely be an asset for their application for cancer prevention
(31).
In summary, a robust generation of GEM models is now available or in the pipeline, which are
based on the restricted loss- or gain-of-function of gene expression in highly selective tissue-
specific compartments and with precise temporal kinetics. Several of these models have already
been validated to the human cancers they emulate, often to specific sub-types of the disease,
and are now being exploited for the development of novel therapeutic approaches in academic
and industrial settings. However, it is important to note that relatively few studies of cancer
prevention have been done using this “next” generation of more sophisticated GEM models of
human cancer. Thus, potential promise of GEM models for cancer prevention research remains
largely unexplored.
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Lessons from the past: successes or failures?
Although GEM models have been relatively under-utilized in prevention research, lessons from
previous studies can help to assess their potential value for cancer prevention in future research.
In particular, the colon is among the best-studied areas of prevention research in which mouse
models have been employed extensively (32,33). This reflects in part, a long-standing tradition
of prevention research in colon cancer, as well as the availability of a chemically-induced
ApcMin (multiple intestinal neoplasia) mouse model of the disease based on mutational loss-
of-function of the Apc (Adenomatosis polyposis coli) gene, which is also mutated in the
Familial Adenomatous Polyposis syndrome and many human colon cancers (32,33). Notably,
while the ApcMin model has been extensively used to gain insights into the mechanisms of
colon carcinogenesis and for prevention research, the phenotype occurs mainly in the small
intestines and is non-invasive, whereas a newer generation of GEM models that develop colon
cancer should provide improved models for colon cancer prevention research (33,34).
Extensive epidemiological evidence has shown that individuals consuming a high-fat
“Western-style” diet have a higher incidence of many cancers and that agents such as Vitamin
D have a protective effect against cancer. Preclinical studies done in the ApcMin model to
investigate the consequences of a Western-style diet, including reduced calcium and vitamin
D and increased fat, for colon carcinogenesis resulted in elevated cancer-rates in the mutant
mice, in agreement with the epidemiological data (32,33). However, some subsequent
prospective clinical trials did not confirm that altering dietary factors led to prevention of colon
cancer (35), which led to concerns about the relevance of these pre-clinical studies in mice for
human colon cancer. Skeptics of using mouse models for cancer prevention have offered these
data as an indictment of the limited relevance of these models to human cancer.
However, proponents of mouse models have noted that the trial design and endpoints of the
clinical trial were quite different than those of the epidemiological and pre-clinical studies, and
have suggested that the discrepancy between these findings may reflect differences in
experimental design rather than an actual differences in between the mouse and human
situations. Indeed, examination of stratified groups in the polyp prevention trial revealed that
the most compliant quartile showed a three-fold reduction in risk of advanced adenoma (36).
Therefore, the data from the mouse models, which are inherently more homogenous and nearly
100% compliant, may recapitulate a sub-group of the human patients. This suggests that the
findings in mouse models may be relevant when appropriate comparisons are made.
Indeed, while it is customary to consider the criteria of the best model, perhaps it may be more
relevant consider the most appropriate model for the experimental question; surely any model,
no matter how relevant, can be considered non-predictive if it is not used in the appropriate
contextual framework. Importantly, since any model will undoubtedly have certain limitations,
the issue is not whether a given model recapitulates every aspect of the human disease (which
would be nearly impossible!) but rather whether it provides reliable information for the
experimental question that is being addressed and whether the experimental design will
ultimately lead to insights that will be applicable to human cancer.
The challenge of using GEM models for cancer prevention
So, why have GEM models been so underutilized in cancer prevention thus far? One important
reason has been the need for model refinement; indeed, GEM models that are likely to be most
effective for prevention research have come on board only recently. As discussed above, these
“next generation” models more closely recapitulate the evolution of cancer progression, more
effectively enable the interrogation of earliest disease stages, and provide valuable models for
pre-clinical assessment. However, in addition, there remain important practical and scientific
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issues that have hampered the use of GEM models in cancer prevention research and will
continue to do so if not addressed.
One key problem is that prevention research requires the integration of multiple scientific
perspectives. Improving ways of bringing together epidemiologists, basic scientists, mouse
modelers, geneticists, bioinformaticians, and clinicians will be imperative for making real
headway in cancer prevention. Unfortunately, communication between these multiple areas of
research have been limited, particularly with respect to the potential application of GEM
models for prevention research. An effective strategy to bridge this gap may be to establish
consortia of prevention researchers, including those with the various complementary expertise
noted above.
A second major problem is one of cost. Preclinical studies in mutant mice are expensive and
difficult to recover from standard funding mechanisms. Although GEM models are now being
increasingly utilized for experimental therapeutics by the pharmaceutical industry, most
prevention research has been focused in academic settings and there has been little opportunity
for cost-sharing with industry. One means of addressing the high cost of these research efforts
would be to establish designated centers for conducting pre-clinical prevention studies that
would bring together on a large-scale expertise in animal handling, pre-clinical design and
implementation, in vivo imaging, pathology, genomics and pharmacology.
Another major stumbling block for virtually all studies using GEM models of cancer is the
lack of sufficient numbers of pathologists that can critically evaluate GEM models relative to
the human cancers they represent. While the involvement of pathologists will be key to the
successful establishment of a concerted effort in applying mouse models to cancer prevention,
the number of veterinary and academic medical pathologists available for such collaborative
efforts is limited. In addition, the adoption of standardized morphologic nomenclature is needed
to facilitate comparison of mouse models with human cancer (37,38). Close working
relationships between veterinary and medical pathologists will be critical for assessment of the
utility of these models
Finally, a significant impediment to the use of GEM models has been intellectual property
issues. In particular, broad patents on the use of genetically-engineered mice for cancer studies
have hampered pre-clinical testing of compounds using GEM models in academic and
industrial settings (9,15). Fortunately, the recognition that GEM models may play a critical
role in identifying compounds that are more likely to succeed in human clinical trials has begun
to accelerate their use in both academic and industry settings (9).
Opportunities for using GEM models for cancer prevention
Despite these challenges, the future of GEM models for cancer prevention is very promising.
The time is now ideal for exploiting a new generation of highly sophisticated mouse models
to address critical issues in cancer prevention (Fig. 1). However, for this to be fully realized,
careful consideration needs to be paid not only to the design of the models but also to the design
of the experimental paradigms in which they are used. Moreover, there is a need to recognize
and overcome the limitations of the model systems, as well as practical limitations that have
hindered their effective use for cancer prevention research.
So, what are the major opportunities for using GEM models to augment prevention research
(Fig. 1)? First of all, GEM models offer a unique opportunity to interrogate the earliest stages
of carcinogenesis in the context of the whole animal. While premalignant lesions are often
inaccessible in humans, they can be readily studied in GEM models, particularly with the
benefit of new imaging modalities. Such studies in GEM models can facilitate our
understanding of the molecular pathways that are deregulated in pre-invasive lesions in
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humans, as well as provide models to test the consequences of targeting such pathways with
chemopreventive agents. Indeed, it would be exceedingly difficult to identify the relevant
pathways in premalignant or early invasive lesions in human cancer, considering their relative
inaccessibility, the overall heterogeneity, and inability to study progression over time.
However, once pathways and mechanisms have been identified in GEM models they can be
readily assessed to evaluate their potential relevance for human cancer.
In addition, since most GEM models are developed from defined genetic alterations,
carcinogenesis is relatively uniform and generally dependent on specific de-regulated
pathways. Therefore, cancer phenotypes in mouse models tend to be relatively homeogenous,
which can help to overcome the problem of biologic variation due to the tremendous genetic
diversity in studying human cancers. As a consequence, GEM models can provide a filter for
the identification of relevant molecular pathways for target validation as well as biomarker
detection. An exciting recent application is the use of serum profiles from GEM models to
identify potential biomarkers for early detection of human cancer (Hanash, S. and Depinho,
R., personal communication)(39). Furthermore, analyses of tumor phenotypes in genetically-
variant strains of mice can help to identify “risk” factors or “modifier” genes that influence
tumor phenotypes (40), which would be exceedingly difficult to identify in humans.
Finally, appropriately designed pre-clinical studies in GEM models can provide an important
resource for investigating the efficacy of novel chemopreventive agents, as well as the
consequences of dietary, chemical, hormonal, and/or environmental influences on
carcinogenesis. In particular, studies in GEM models can enable the initial testing of single
agents, or evaluate the efficacy of combinations of agents, which have potential
chemopreventive benefit, and can also provide initial insights into their toxicity limits and
mechanisms of action in vivo (9,41). Moreover, GEM models offer a resource for investigating
the consequences of environomental influences, such as the contribution of diet, the intestinal
flora, or hormonal influences for carcinogenesis (42–44).
In summary, GEM models offer a unique opportunity for providing biological and mechanistic
insights regarding the interplay between genetic and environmental factors that influence
cancer initiation as well as pre-clinical models to test the consequences of targeting specific
factors for alleviating carcinogenesis. While analyses of mouse models will never be a suitable
replacement for human clinical studies, such analyses can surely aid in the refinement of such
studies to the considerable benefit of the human population assuming that the appropriate
models are used in the appropriate experimental paradigms.
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Table 1
Type of model Common Uses Advantages Disadvantages
Transgenic Gain of oncogene function Ease and simplicity of design and
use Classic models are still
relevant
Forced expression may not model
disease evolution Requires tissue-
specific promoter
Germline deletion Loss of tumor suppressor function Initial insights of tumor suppressor
function Classic models are still
relevant
Model inherited rather than sporadic
cancer Homozygous deletion often
results in lethality
Conditional gene targeting Gain or loss of function Overcome embryonic lethality
Tissue specific phenotypes
Require tissue-specific promoter
expressing Cre Recombination often
in many cells, not stochastic
Cre-inducible gene targeting
Via Cre mouse alleles Gain or loss of function Control spatial, temporal, and
extent of gene targeting
Require inducible Cre alleles Matings
are complex
via viral delivery Gain or loss of function Viral delivery is stochastic and not
directed to a specific cell type
Targeting multiple cell types can lead
to heterogeneity
Tet-regulatable models Gain or loss of function Reversible spatial and temporal
control of gene expression
Long-term investiment for multiple
targeting alleles Matings are complex
TVA models Gain of function Stochastic spatial and temporal
regulation
Need specialized mouse alleles for
tissue of interestVirus infects
replicating cells
RNAi gene silencing Loss of function Control levels of gene expression
Can be reversible
Possible off target effects Technology
is still in development
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